


CVT-12012

Cat. No.:	HY-11034		
CAS No.:	1018675-35-8		
Molecular Formula:	C ₂₁ H ₂₁ F ₃ N ₄ O ₃		
Molecular Weight:	434.41		
Target:	Stearoyl-CoA Desaturase (SCD)		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (287.75 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	Preparing Stock Solutions	1 mM	2.3020 mL	11.5099 mL
		5 mM	2.3020 mL	4.6039 mL
		10 mM	0.2302 mL	1.1510 mL
			10 mg	2.3020 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution			
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	CVT-12012 is a potent and orally bioavailable stearoyl-coA desaturase (SCD) inhibitor, with IC ₅₀ s of 38 nM, 6.1 nM for rat microsomal and human HEPG2, respectively.
IC ₅₀ & Target	IC ₅₀ : 38 nM (rat microsomal), 6.1 nM (human HEPG2) ^{[1][2]} .
In Vitro	CVT-12012 (Compound 5b) displays the highest potency in both the microsomal and the HEPG2 SCD assays (IC ₅₀ 38 nM and 6.1 nM, respectively) compared to the other methyl-substituted compounds ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In a rat PK study, CVT-12012 demonstrates good oral bioavailability (78%). It appears that the oral absorption of CVT-12012 is not affected by a significant Pgp efflux, which is expected based on Caco-2 assay result. The plasma clearance of CVT-12012 is high (88 mL/min/kg) with elimination half-life of approximately 1 h^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Koltun DO, et al. Potent, orally bioavailable, liver-selective stearyl-CoA desaturase (SCD) inhibitors. *Bioorg Med Chem Lett*. 2009 Aug 1;19(15):4070-4.

[2]. Atkinson KA, et al. N-benzylimidazole carboxamides as potent, orally active stearylCoA desaturase-1 inhibitors. *Bioorg Med Chem Lett*. 2011 Mar 15;21(6):1621-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA